I
Itai Danovitch
Researcher at Cedars-Sinai Medical Center
Publications - 50
Citations - 1629
Itai Danovitch is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Randomized controlled trial & Quality of life. The author has an hindex of 16, co-authored 43 publications receiving 1080 citations. Previous affiliations of Itai Danovitch include University of California, Los Angeles & University of California.
Papers
More filters
Journal ArticleDOI
Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study
Alexander J Steiner,Jennifer Recacho,Brigitte Vanle,Jonathan Dang,Stephanie M. Wright,Justin S Miller,Kaitlyn Kauzor,Mark W. Reid,Luma Bashmi,James Mirocha,Itai Danovitch,Itai Danovitch,Waguih William IsHak +12 more
TL;DR: Findings suggest that older adults and younger adults have comparable treatment responses to citalopram monotherapy, with significant improvements in patient-reported depressive symptom severity, functioning, and QOL.
Journal ArticleDOI
The Clinical Assessment and Treatment of Nicotine Dependence
TL;DR: The epidemiology and pathophysiology of nicotine dependence is summarized as a background for reviewing the central components of clinical evidence-based smoking cessation interventions: screening, assessment, advice, assistance, and follow-up.
Journal ArticleDOI
The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review.
Rebecca Hedrick,Samuel Korouri,Emile Tadros,Tarneem Darwish,Veronica Cortez,Desiree Triay,Mia Pasini,Linda Olanisa,Nathalie Herrera,Sophia Hanna,Asher Kimchi,Michele A. Hamilton,Itai Danovitch,Waguih William IsHak +13 more
TL;DR: Although early analyses have pointed to an association of antidepressant use and mortality particularly with fluoxetine, the reviewed studies showed no increase in mortality for antidepressants, and secondary analyses showed improved mortality in patients who achieved remission of depressive symptoms.
Journal ArticleDOI
Analysis of Patient-reported Outcomes of Quality of Life and Functioning Before and After Treatment of Major Depressive Disorder Comorbid With Alcohol Use Disorders.
Itai Danovitch,Alexander J Steiner,Anna Kazdan,Matthew Goldenberg,Margaret Haglund,James Mirocha,Katherine L. Collison,Brigitte Vanle,Jonathan Dang,Waguih William IsHak +9 more
TL;DR: Findings suggest that subjects with MDD + AUD benefited equally as MDD-no-AUD from treatment with selective serotonin reuptake inhibitors (SSRI) medication, yet both groups continue to experience reduced QOL and functioning after treatment.